Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Molecule-1
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Molecule-1 is an experimental small molecule hybrid designed as a histone deacetylase (HDAC) inhibitor for the treatment of cancer. It was developed to address the toxicity and poor pharmacokinetic properties of traditional hydroxamate-based HDAC inhibitors, such as vorinostat, by incorporating natural antioxidant pharmacophores into its structure. The molecule aims to provide antineoplastic activity through epigenetic modulation, specifically by inhibiting HDAC enzymes to reactivate tumor suppressor genes. Its design was guided by in silico studies and molecular docking to optimize binding affinity and selectivity toward the HDAC catalytic site while potentially improving the safety profile compared to first-generation agents.
Beyond the preview
Go deeper on Molecule-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Molecule-1.